Earnings Releases·Nov 10, 2026, 4:06 PM ET

Dermata Therapeutics — Third Quarter 2026 Earnings Summary

Net sales reached $74,000 in Q3 2026 versus $0 in the prior year period, resulting in a net loss of $2.8 million ($0.55 per share) compared to a $1.7 million loss ($1.65 per share) in Q3 2025.
Cash and equivalents declined to $5.0 million as of September 30, 2026, from $7.5 million at year-end 2025, though the company raised $5.2 million in net proceeds via ATM financing and an August 2026 transaction to fund operations into Q1 2027.
SG&A expenses increased to $2.8 million from $1.3 million year-over-year, driven by a $0.8 million rise in legal fees, $0.5 million in compensation reallocation to commercialization, and $0.2 million in marketing costs.
The company launched its first commercial product, Tome Foundational Treatment, in August 2026, with approximately 30% of orders via subscription, and expects to launch the second product, Tome Clearing Treatment, in the first half of 2027.